UBS Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $223M | Buy |
1,030,150
+506,700
| +97% | +$96.9M | 0.03% | 606 |
|
|
2026
Q1 | $96M | Sell |
523,450
-118,338
| -18% | -$21.8M | 0.01% | 1083 |
|
|
2025
Q4 | $113M | Buy |
641,788
+2,823
| +0.4% | +$461K | 0.02% | 949 |
|
|
2025
Q3 | $89.5M | Buy |
638,965
+193,281
| +43% | +$26.1M | 0.01% | 1115 |
|
|
2025
Q2 | $56M | Sell |
445,684
-200,463
| -31% | -$25M | 0.01% | 1412 |
|
|
2025
Q1 | $88.4M | Sell |
646,147
-402,272
| -38% | -$57.5M | 0.02% | 1006 |
|
|
2024
Q4 | $160M | Buy |
1,048,419
+544,566
| +108% | +$91.9M | 0.03% | 626 |
|
|
2024
Q3 | $97.7M | Buy |
503,853
+51,342
| +11% | +$10.7M | 0.02% | 734 |
|
|
2024
Q2 | $105M | Sell |
452,511
-23,315
| -5% | -$5.07M | 0.03% | 631 |
|
|
2024
Q1 | $103M | Buy |
475,826
+137,472
| +41% | +$32.2M | 0.03% | 634 |
|
|
2023
Q4 | $87.6M | Sell |
338,354
-81,444
| -19% | -$20M | 0.03% | 641 |
|
|
2023
Q3 | $108M | Buy |
419,798
+27,066
| +7% | +$7.24M | 0.04% | 476 |
|
|
2023
Q2 | $112M | Buy |
392,732
+96,648
| +33% | +$28.8M | 0.04% | 450 |
|
|
2023
Q1 | $82.3M | Buy |
296,084
+1,809
| +0.6% | +$501K | 0.03% | 535 |
|
|
2022
Q4 | $81.5M | Buy |
294,275
+147,458
| +100% | +$41.6M | 0.03% | 573 |
|
|
2022
Q3 | $39.2M | Sell |
146,817
-132,493
| -47% | -$28.1M | 0.02% | 824 |
|
|
2022
Q2 | $57M | Sell |
279,310
-84,208
| -23% | -$17.2M | 0.02% | 661 |
|
|
2022
Q1 | $76.6M | Buy |
363,518
+1,406
| +0.4% | +$306K | 0.03% | 624 |
|
|
2021
Q4 | $86.9M | Buy |
362,112
+48,149
| +15% | +$12.4M | 0.02% | 662 |
|
|
2021
Q3 | $88.8M | Buy |
313,963
+74,754
| +31% | +$24.5M | 0.03% | 580 |
|
|
2021
Q2 | $82.8M | Buy |
239,209
+40,143
| +20% | +$12.2M | 0.03% | 595 |
|
|
2021
Q1 | $55.7M | Sell |
199,066
-34,199
| -15% | -$9.22M | 0.02% | 778 |
|
|
2020
Q4 | $57.1M | Buy |
233,265
+97,735
| +72% | +$25.2M | 0.02% | 723 |
|
|
2020
Q3 | $38.4M | Sell |
135,530
-180,410
| -57% | -$50.3M | 0.01% | 787 |
|
|
2020
Q2 | $84.5M | Buy |
315,940
+52,443
| +20% | +$15.8M | 0.04% | 422 |
|
|
2020
Q1 | $83.4M | Sell |
263,497
-6,502
| -2% | -$1.97M | 0.04% | 399 |
|
|
2019
Q4 | $80.1M | Sell |
269,999
-118,267
| -30% | -$32.8M | 0.03% | 532 |
|
|
2019
Q3 | $90.4M | Buy |
388,266
+53,176
| +16% | +$12.4M | 0.03% | 436 |
|
|
2019
Q2 | $78.4M | Sell |
335,090
-15,209
| -4% | -$3.51M | 0.03% | 478 |
|
|
2019
Q1 | $82.8M | Buy |
350,299
+149,084
| +74% | +$46.9M | 0.03% | 437 |
|
|
2018
Q4 | $60.5M | Sell |
201,215
-170,596
| -46% | -$54.4M | 0.03% | 510 |
|
|
2018
Q3 | $131M | Buy |
371,811
+50,901
| +16% | +$17.5M | 0.05% | 332 |
|
|
2018
Q2 | $93.1M | Sell |
320,910
-36,357
| -10% | -$10.2M | 0.04% | 421 |
|
|
2018
Q1 | $97.8M | Sell |
357,267
-84,362
| -19% | -$26.2M | 0.04% | 393 |
|
|
2017
Q4 | $141M | Buy |
441,629
+242,120
| +121% | +$77.7M | 0.06% | 319 |
|
|
2017
Q3 | $62.5M | Sell |
199,509
-86,808
| -30% | -$25.7M | 0.03% | 513 |
|
|
2017
Q2 | $77.7M | Buy |
286,317
+111,258
| +64% | +$29.4M | 0.04% | 416 |
|
|
2017
Q1 | $47.9M | Buy |
175,059
+932
| +0.5% | +$264K | 0.03% | 566 |
|
|
2016
Q4 | $49.4M | Sell |
174,127
-142,594
| -45% | -$42.3M | 0.03% | 551 |
|
|
2016
Q3 | $99.1M | Buy |
316,721
+57,960
| +22% | +$17.2M | 0.06% | 321 |
|
|
2016
Q2 | $62.6M | Buy |
258,761
+9,013
| +4% | +$2.38M | 0.04% | 421 |
|
|
2016
Q1 | $65M | Sell |
249,748
-235,101
| -48% | -$62.1M | 0.04% | 390 |
|
|
2015
Q4 | $149M | Buy |
484,849
+284,807
| +142% | +$81.8M | 0.1% | 223 |
|
|
2015
Q3 | $58.4M | Buy |
200,042
+56,857
| +40% | +$18.8M | 0.04% | 419 |
|
|
2015
Q2 | $57.8M | Buy |
143,185
+3,827
| +3% | +$1.54M | 0.04% | 470 |
|
|
2015
Q1 | $58.8M | Sell |
139,358
-9,607
| -6% | -$3.79M | 0.04% | 450 |
|
|
2014
Q4 | $50.6M | Buy |
+148,965
| New | +$48.2M | 0.04% | 533 |
|
Other funds holding BIIB
UBS Group's BIIB Position: Q2 2026 in Review
UBS Group increased its Biogen (BIIB) stake by 97% in Q2 2026, buying an estimated $96.9M and bringing the position to 1,030,150 shares worth $223M. The position accounts for 0.03% of the portfolio, ranked #606.
UBS Group first reported a position in BIIB in Q4 2014 and has held it in 47 quarters since. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- UBS Group held 1,030,150 shares of Biogen worth $223M as of Q2 2026.
- UBS Group bought 506,700 Biogen shares in Q2 2026, an estimated $96.9M.
- Biogen made up 0.03% of UBS Group's portfolio in Q2 2026, its #606 holding.
- UBS Group first reported a position in Biogen in Q4 2014 and has held it in 47 quarters since.
- 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.